Patrick Vallance appointed to GSK executive leadership team

GlaxoSmithKline (GSK) today announced the appointment of Patrick Vallance, as Senior Vice President, Medicines Discovery and Development and as a member of the company Corporate Executive Team both with effect from 1st July 2010.

Issued: London UK

GlaxoSmithKline (GSK) today announced the appointment of Patrick Vallance, as Senior Vice President, Medicines Discovery and Development and as a member of the company’s Corporate Executive Team both with effect from 1st July 2010.

Andrew Witty, Chief Executive Officer, GSK commented: “Patrick has a deep level of scientific and medical acumen, which coupled with his proven management skills, mean he is well placed to bring further R&D perspective to GSK’s leadership team. This appointment aligns with the company’s drive to increase R&D productivity and deliver more products of value. I look forward to working with Patrick in his new role and welcome him to the executive team.”

Prior to joining GSK in 2006, Patrick was a clinical academic and led the Division of Medicine at UCL. He has over 20 years of experience of clinical medicine and has an international reputation as a vascular biologist and clinician scientist. He was elected to the Academy of Medical Sciences in 1999, and subsequently became its Registrar before leaving to join GSK.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

   

UK Media enquiries:

Philip Thomson

(020) 8047 5502

 

Claire Brough

(020) 8047 5502

 

Stephen Rea

(020) 8047 5502

 

Alexandra Harrison

(020) 8047 5502

 

Jo Revill

(020) 8047 5502

 

 

 

US Media enquiries:

Nancy Pekarek

(919) 483 2839

 

Mary Anne Rhyne

(919) 483 2839

 

Kevin Colgan

(919) 483 2839

 

Sarah Alspach

(919) 483 2839

 

   

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564

 

Sally Ferguson

(020) 8047 5543

 

Gary Davies

(020) 8047 5503

     

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

 

Jen Hill Baxter

(215) 751 7002

Back to top